HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genzyme launches Sepracoat in UK:

This article was originally published in Clinica

Executive Summary

Genzyme launched its Sepracoat liquid barrier in the UK last week. Sepracoat is used during surgery to coat tissue and protect it from incidental trauma caused by drying, handling and contact with surgical instruments and materials. The viscous coating is made from a concentrated solution of hyaluronic acid, a substance which occurs naturally in the body. Sepracoat remains at the site of surgery for about 24 hours and is resorbed by the body in about five days. Genzyme, based in Cambridge, Massachusetts, is selling Sepracoat as an accompaniment to its Seprafilm physical barrier which is placed between tissues and organs after surgery to avoid adhesions.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT083552

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel